eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, is an activator of anti-tumor immune response

被引：0
|
作者：
Webster, Kevin [1 ]
Sharma, Rajesh [1 ]
Goel, Vikas [1 ]
Stumpf, Craig [1 ]
Stauton, Jocelyn [1 ]
Thompson, Peggy [1 ]
Chiang, Gary [1 ]
Xu, Yichen [2 ]
Jin, Hyun Yong [2 ]
Ruggero, Davide [2 ]
机构：
[1] eFFECTOR Therapeut, San Diego, CA USA
[2] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2017年 / 5卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P368
引用
收藏
页数：2
相关论文
共 50 条
  • [1] eFT508: An oral, potent and highly selective inhibitor of MNK1 and MNK2, promotes anti-tumor immunity as a monotherapy and in combination with immune checkpoint blockade
    Webster, Kevin R.
    Goel, Vikas K.
    Staunton, Jocelyn
    Hung, Ivy N. J.
    Parker, Gregory S.
    Stumpf, Craig R.
    Molter, Jolene
    Chiang, Gary G.
    Wegerski, Christopher J.
    Sperry, Samuel
    Chen, Joan
    Huang, Vera
    Thompson, Peggy A.
    Tran, Chinh
    Ernst, Justin T.
    Webber, Stephen E.
    Sprengeler, Paul A.
    Reich, Siegfried H.
    CANCER RESEARCH, 2017, 77
  • [2] eFT508, a potent and highly selective inhibitor of MNK1 and MNK2, regulates T-cell differentiation promoting an antitumor immune response
    Sharma, Rajesh K.
    Goel, Vikas K.
    Staunton, Jocelyn
    Barrera, Maria
    Parra, Ana
    Sung, Eric
    Chiang, Gary G.
    Webster, Kevin R.
    CANCER RESEARCH, 2018, 78 (13)
  • [3] eFT508, a potent and highly selective inhibitor of MNK1/2 regulates immune checkpoint and cytokine expression promoting anti-tumor immunity
    Webster, Kevin R.
    Goel, Vikas K.
    Staunton, Jocelyn
    Stumpf, Craig R.
    Sharma, Rajesh
    Hung, Ivy N.
    Parker, Gregory S.
    Molter, Jolene
    Chiang, Gary G.
    Wegerski, Christopher J.
    Sperry, Samuel
    Huang, Vera
    Chen, Joan
    Thompson, Peggy A.
    Tran, Chinh
    Ernst, Justin T.
    Sprengeler, Paul A.
    Reich, Siegfried H.
    CANCER RESEARCH, 2017, 77
  • [4] Tomivosertib (eFT508), a potent and highly selective inhibitor of MNK1 and MNK2, enhances CAR T cell activity through modulating T cell differentiation
    Goel, Vikas K.
    Sharma, Rajesh K.
    Staunton, Jocelyn
    Stumpf, Craig R.
    Young, Nathan P.
    Thompson, Peggy A.
    Chiang, Gary G.
    Webster, Kevin R.
    CANCER RESEARCH, 2019, 79 (13)
  • [5] A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of eFT508, a Selective, Orally Bioavailable Inhibitor of MNK1 and MNK2, in Patients with Hematological Malignancies
    Gopal, Ajay K.
    Ramchandren, Rod
    Gabrail, Nashat Y.
    Patel, Manish R.
    Wang, Ding
    Miller, Langdon L.
    Goel, Vikas
    Chiang, Gary G.
    Webster, Kevin R.
    Sperry, Sam
    Vallner, Debra T.
    Casseday, Cara
    Barton, Jeremy
    BLOOD, 2017, 130
  • [6] Repression of tumor survival pathways by novel, selective inhibitors of MNK1 and MNK2 kinases
    Rzymski, Tomasz
    Dreas, Agnieszka
    Milik, Mariusz
    Kucwaj, Katarzyna
    Zarebski, Adrian
    Skuta, Malgorzata Szajewska
    Cierpich, Anna
    Fabritius, Charles
    Brzozka, Krzysztof
    CANCER RESEARCH, 2013, 73
  • [7] Identification of a Highly Conserved Allosteric Binding Site on Mnk1 and Mnk2
    Basnet, Sunita K. C.
    Diab, Sarah
    Schmid, Raffaella
    Yu, Mingfeng
    Yang, Yuchao
    Gillam, Todd Alexander
    Teo, Theodosia
    Li, Peng
    Peat, Tom
    Albrecht, Hugo
    Wang, Shudong
    MOLECULAR PHARMACOLOGY, 2015, 88 (05) : 935 - 948
  • [8] Repression of tumor survival pathways by novel and selective inhibitors of MNK1 and MNK2 kinases in glioblastoma and colorectal cancer
    Rzymski, Tomasz
    Szajewska-Skuta, Malgorzata
    Zarebski, Adrian
    Sitarz, Kamil
    Sapala, Lukasz
    Zurawska, Malgorzata
    Salwinska, Magdalena
    Windak, Renata
    Trebacz, Ewa
    Daniel-Wojcik, Joanna
    Obuchowicz, Radoslaw
    Winnik, Bozena
    Wincza, Ewelina
    Kulesza, Urszula
    Kucwaj-Borysz, Katarzyna
    Milik, Mariusz
    Dreas, Agnieszka
    Brzozka, Krzysztof
    CANCER RESEARCH, 2014, 74 (19)
  • [9] Inhibition of MNK by eFT508 reprograms T-cell signaling to promote an antitumor immune response
    Stumpf, Craig R.
    Chen, Joan
    Goel, Vikas K.
    Parker, Gregory S.
    Chiang, Gary G.
    Thompson, Peggy A.
    Webster, Kevin R.
    CANCER RESEARCH, 2018, 78 (13)
  • [10] Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development
    Ueda, Takeshi
    Sasaki, Masato
    Elia, Andrew J.
    Chio, Iok In Christine
    Hamada, Koichi
    Fukunaga, Rikiro
    Mak, Tak W.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (32) : 13984 - 13990
12345